Thymalin — questions, answered plainly.

Thymalin is a peptide complex extracted from calf thymus tissue, developed by the Khavinson group in St Petersburg, Russia. It is not a single defined sequence — it is a mixture of short peptides isolated from thymic tissue.

No. Thymalin is registered as a preparation in the Russian Federation but is not FDA-approved (US), MHRA-approved (UK), or EMA-approved (EU).

The Khavinson 2020 paper (Bull Exp Biol Med, PMID 33237528) reports thymalin-associated reduction of stem-cell markers and elevation of CD28+ expression in human hematopoietic stem cell assays. The Khavinson 2002 paper (PMID 12374906) places thymalin within a broader geroprotective-peptides framework. The Lin'kova 2011 review (PMID 21809618) covers the pineal-thymus axis.

No. Thymalin is a thymic peptide extract (mixture) developed by the Khavinson group in Russia. Thymosin Alpha-1 is a chemically defined 28-residue synthetic peptide marketed as Zadaxin / thymalfasin. They are distinct compounds with separate development histories.

The Khavinson research network in St Petersburg has produced the majority of peer-reviewed thymalin literature over four decades. Independent replication outside this network is limited; this is a documented evidence caveat rather than an editorial judgement.

The peer-reviewed evidence base is concentrated within a single research network. Independent replication is limited. Thymalin is not approved by FDA, MHRA, or EMA; Russian-Federation registered status does not constitute approval elsewhere.